Evidence map›Paper›PMID 41362455›Full record

ArticleMaterials today. Bio2025

Multilayer surface coating for enhanced anti-inflammation, anti-restenosis, and re-endothelialization in advanced biodegradable vascular stents.

Duck Hyun Song, Seungwoon Baik, Jun Yong Kim, Jeong Min Park, Byeongseok Ryu, Il Ho Seo, Su Sam Lee, Han Byul Kim, Young Joon Hong, Won-Gun Koh and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Duck Hyun SongDepartment of Biomedical Science, CHA University, South Korea.
Seungwoon BaikORANDBIO Co., Ltd., South Korea.
Jun Yong KimDepartment of Biomedical Science, CHA University, South Korea.
Jeong Min ParkDepartment of Biomedical Science, CHA University, South Korea.
Byeongseok RyuDepartment of Chemical and Biomolecular Engineering, Yonsei University, South Korea.
Il Ho SeoDepartment of Mechanical Engineering, Yonsei University, South Korea.
Su Sam LeeDepartment of Chemical & Biomolecular Engineering, Korea Advanced Institute of Science and Technology, South Korea.
Han Byul KimDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Science, Seoul, South Korea.
Young Joon HongDivision of Cardiology, Chonnam National University Hospital, South Korea.
Won-Gun KohDepartment of Chemical and Biomolecular Engineering, Yonsei University, South Korea.
WonHyoung RyuDepartment of Mechanical Engineering, Yonsei University, South Korea.
Yeu-Chun KimDepartment of Chemical & Biomolecular Engineering, Korea Advanced Institute of Science and Technology, South Korea.
Dong Ryul LeeDepartment of Biomedical Science, CHA University, South Korea.
Dong Keun HanORANDBIO Co., Ltd., South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary artery disease (CAD) remains a leading cause of mortality worldwide, while conventional drug-eluting stents (DES) face limitations in long-term safety and controlled drug release. Here, we developed a poly (L-lactic acid) (PLLA)-based biodegradable vascular scaffold (BVS) with a three-layer coating using distinct technologies for spatiotemporal drug delivery. The luminal surface was selectively coated via electrospraying with alpha-lipoic acid (ALA) to promote endothelialization. The abluminal surface was treated using ultrasonic spray coating with magnesium hydroxide (MH) and everolimus (EVL) to suppress smooth muscle cell proliferation and inflammation. Finally, a precision dot-printing method was employed to deliver doxorubicin (DOX) for early inhibition of restenosis. This strategy enabled time- and site-specific drug release, achieving antioxidant, anti-inflammatory, and

Indexed as

Anti-inflammationControlled drug releaseCoronary artery disease (CAD)Endothelial regenerationRestenosis preventionSpatiotemporal drug delivery

Identifiers

PMID41362455
PMCPMC12681855

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.